Target Name: MIR938
NCBI ID: G100126327
Review Report on MIR938 Target / Biomarker Content of Review Report on MIR938 Target / Biomarker
Other Name(s): hsa-miR-938 | hsa-mir-938 | MIRN938 | MicroRNA 938 | microRNA 938

MIR938: A promising drug target and biomarker in disease therapy

As scientific research continues to unravel the complex mechanisms underlying human diseases, the identification of effective drug targets and biomarkers has become crucial for improved therapeutic interventions. In recent years, MIR938, a small non-coding RNA molecule, has emerged as a promising candidate for both drug targeting and biomarker development. In this article, we will explore the significance of MIR938 and its potential applications in disease therapy.

Understanding the role of MIR938
MIR938 belongs to the family of microRNAs (miRNAs), which are small regulatory RNA molecules involved in gene expression regulation. Although miRNAs account for a small portion of the genome, they exert significant influence by targeting specific messenger RNA (mRNA) molecules for degradation or translational repression. MIR938, specifically, has gained attention due to its involvement in various disease processes, including cancer, cardiovascular diseases, and neurodegenerative disorders.

MIR938 as a drug target
One of the most exciting aspects of MIR938 is its potential as a therapeutic target. By inhibiting or enhancing the activity of MIR938, researchers believe it is possible to modulate disease progression and improve patient outcomes. For example, in certain cancer types, MIR938 has been found to suppress the expression of tumor suppressor genes, thus promoting tumor growth and metastasis. Consequently, specific MIR938 inhibitors could be developed to counteract its oncogenic effects and impede cancer progression.

Similarly, in cardiovascular diseases, MIR938 has been implicated in the regulation of genes involved in cardiac remodeling, fibrosis, and inflammation. By manipulating MIR938 levels, it may be possible to mitigate the detrimental effects of these diseases and promote cardiac health.

MIR938 as a biomarker
Beyond its potential as a drug target, MIR938 also holds promise as a biomarker for disease diagnosis and prognosis. Several studies have shown that aberrant expression of MIR938 is associated with certain diseases and can serve as an indicator of disease severity or treatment response.

For instance, in neurodegenerative disorders such as Alzheimer's and Parkinson's disease, altered levels of MIR938 have been observed in cerebrospinal fluid and brain tissue samples. These findings suggest that MIR938 could serve as a valuable biomarker for early detection and monitoring of disease progression.

In cancer, MIR938 expression profiles have been correlated with patient response to certain chemotherapeutic agents, providing insights into potential personalized treatment strategies. By analyzing MIR938 levels in tumor tissue or circulating biomarkers, clinicians may be able to predict treatment outcomes and tailor therapies accordingly.

Challenges and future prospects
While the potential of MIR938 as a drug target and biomarker is promising, several challenges need to be overcome for its successful translation into clinical practice. Standardization of detection methods, establishment of appropriate cutoff values, and large-scale validation studies are imperative for the reliable and accurate use of MIR938 in disease diagnosis and treatment.

Additionally, further research is needed to unravel the intricate mechanisms by which MIR938 influences gene expression and disease processes. Understanding these underlying mechanisms will be vital for developing targeted therapies that exploit the therapeutic potential of MIR938 effectively.

MIR938 has emerged as a fascinating molecule in the field of disease therapy, offering dual potential as a valuable drug target and biomarker. Its ability to modulate gene expression and its association with numerous diseases highlight its significance as a therapeutic intervention. Nevertheless, additional research and clinical validation are required before MIR938 can be effectively utilized in clinical practice. With ongoing advancements in the field of miRNA research, it is hopeful that MIR938 will play a transformative role in disease management, ultimately improving patient outcomes and quality of life.

Protein Name: MicroRNA 938

The "MIR938 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR938 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

MIR939 | MIR940 | MIR941-1 | MIR941-2 | MIR941-3 | MIR941-4 | MIR941-5 | MIR942 | MIR943 | MIR944 | MIR95 | MIR96 | MIR98 | MIR99A | MIR99AHG | MIR99B | MIRLET7 | MIRLET7A1 | MIRLET7A2 | MIRLET7A3 | MIRLET7B | MIRLET7BHG | MIRLET7C | MIRLET7D | MIRLET7E | MIRLET7F1 | MIRLET7F2 | MIRLET7G | MIRLET7I | MIS12 | MIS12 complex | MIS18A | MIS18A-AS1 | MIS18BP1 | MISFA | MISP | MISP3 | MITD1 | MITF | Mitochondrial complex I assembly complex | Mitochondrial import inner membrane translocase 23 (TIM23) complex | Mitochondrial inner membrane protease complex | Mitochondrial membrane ATP synthase | Mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) | Mitochondrial pyruvate carrier complex (MPC) | Mitochondrial RNA processing endoribonuclease | Mitofilin Complex | Mitofusin | Mitogen-Activated Protein Kinase | Mitogen-activated protein kinase (JNK) | Mitogen-Activated Protein Kinase (MAP Kinase)-Activated Protein Kinase | Mitogen-Activated Protein Kinase Kinase Kinase (MAP3K) | Mitogen-activated protein kinase p38 (MAPK p38) | MITRAC complex | MIX23 | MIXL1 | MKI67 | MKKS | MKLN1 | MKLN1-AS | MKNK1 | MKNK1-AS1 | MKNK2 | MKRN1 | MKRN2 | MKRN2OS | MKRN3 | MKRN4P | MKRN7P | MKRN9P | MKS1 | MKX | MLANA | MLC1 | MLEC | MLF1 | MLF1-DT | MLF2 | MLH1 | MLH3 | MLIP | MLIP-AS1 | MLKL | MLLT1 | MLLT10 | MLLT10P1 | MLLT11 | MLLT3 | MLLT6 | MLN | MLNR | MLPH | MLST8 | MLX | MLXIP | MLXIPL | MLYCD | MMAA | MMAB | MMACHC